Leerink Partners Downgrades Fusion Pharmaceuticals (FUSN) to Market Perform

March 19, 2024 6:03 AM

Leerink Partners analyst Faisal Khurshid downgraded Fusion Pharmaceuticals (NASDAQ: FUSN) from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found